RxDoctor Payments Data

Hemalatha Iyer, MD

Internal Medicine · Texas City, TXNPI 1386638385

Payments from drug & device makers

$939in general payments, 2019–2025

Across 42 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$371
  • GSK$108
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$73
  • Novo Nordisk$70
  • Novartis$67
  • Inspire Medical Systems, Inc.$36
  • plus $214 from 9 others

What the payments were for

  • Food & beverage$939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$939 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$116,915
Medicare patients
236
Services billed
2,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$241,925
FarxigaDapagliflozin Propanediol171$164,584
EliquisApixaban134$136,935
JardianceEmpagliflozin113$134,724
TrulicityDulaglutide60$91,429
MounjaroTirzepatide36$60,622
ProliaDenosumab34$56,661
EntrestoSacubitril/Valsartan64$55,354
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$47,853
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$36,222
Tresiba Flextouch U-200Insulin Degludec30$29,013
RybelsusSemaglutide17$22,955
JanuviaSitagliptin Phosphate18$20,387
XareltoRivaroxaban15$18,504
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$17,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$70$264,880169 claims
Lilly USA, LLCTrulicity, Mounjaro$31$152,05196 claims
Boehringer IngelheimJardiance, Synjardy Xr, Jentadueto$21$147,636140 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$108$98,330135 claims
NovartisEntresto$67$55,35464 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Texas City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →